E-mail us
In-Silico PBPK Modeling and Simulation

Advanced In Silico Data to Accelerate to First in Human

Optimize your pre-clinical and clinical dosing strategies through PK simulations


After completing your molecule's basic benchwork and characterization, it is time to leverage powerful simulation software for in vitro-in vivo extrapolation.

Too many biotechs rely on obsolete methods when moving into in vivo studies. Without a model-informed understanding of your molecule's ADMET (absorption, distribution, metabolism, excretion, and toxicology) properties prior to pre-clinical studies, your program is at risk of:

Integrating in silico advancements into your program will help you expedite your timeline for CMC (chemistry, manufacturing, and controls) and dosing strategies. 

As a result, your regulatory filings will be streamlined by minimizing the amount of pre-clinical studies needed.

What would normally take several in vivo studies, can now be achieved through faster, less expensive in silico innovations.

Accelerate to FIH with Model-Informed Drug Development and Regulatory Interactions

Physiologically-based pharmacokinetic (PBPK) modeling enables decisive actions to achieve First in Human (FIH) dosing strategies and faster commercial development.

From your molecule's chemical properties, this innovative software can extrapolate in silico predictions for:

Using this information, you can make well-informed decisions on the appropriate pre-clinical animal study.

Scaling Data Across Species and Into Humans


Shortening your clinical development timeline with in silico FIH dose selection and formulation optimization is possible and can improve the following:

A strong understanding of human ADMET properties before reaching FIH allows for effective dosing strategies and more efficient regulatory interactions. 


Leave a Message

Related Updates in Crystal Pharmatech

Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303